Involved in the "first major bidding case of national procurement", ApicHope Pharmaceutical may face its first loss after going public | Interpretations

① Due to the continued increase in research and development investment, reimbursement of medical insurance refunds, and other factors, ApicHope Pharmaceutical may experience its first loss since its listing in 2024. ② It is expected that the net loss in Q4 will be between 0.225 billion yuan and 0.433 billion yuan.

cls.cnJan 22 23:27

6 popular stocks with 4 limit-ups in 6 days: A wholly-owned subsidiary plans to invest in the construction of a "new project" | Selected post-market announcements.

In 6 days, 4 hot stocks in the Robot Concept, the subsidiary plans to invest in the construction of a "new project," a leading financial IT company worth billions will change ownership, and the "number one" in PC security products is expected to have a Net income loss in the 2024 fiscal year...

Golden10 DataJan 17 20:58

Ginwa Enterprise(Group) Inc. and several senior executives have been criticized for violations of information disclosure regulations! The Chairman has just been placed under investigation | Quick Reading of Announcement.

① Due to violations of information disclosure and the use of raised funds for stock trading, Ginwa Enterprise(Group) Inc. and several senior executives including Director Xing Yajiang have been criticized. Additionally, Xing Yajiang is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws. ② According to Tianyancha, from the end of 2019 to the present, Ginwa Enterprise(Group) Inc. and personnel including Xing Yajiang have received a total of 60 penalties from the Shanghai Stock Exchange, the China Securities Regulatory Commission, and others.

cls.cnJan 14 23:43

High R&D investment and a decline in the terminal hospitalization price of products have resulted in Beijing Hotgen Biotech Co., Ltd turning from profit to loss in 2024, with Q4 net profit decreasing almost fivefold year-on-year.

① Regarding the main reasons for the decline in performance, Beijing Hotgen Biotech Co.,Ltd attributes it to high R&D investment, intensified competition in the Industry, and increased R&D investment from joint ventures. ② As medical centralized procurement continues to advance, competition within the Industry intensifies, leading to further declines in the terminal hospitalization prices of products, and Beijing Hotgen Biotech Co.,Ltd's single machine revenue and output rate have shown varying degrees of decline.

cls.cnJan 14 21:09

The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.

① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.

cls.cnJan 6 21:42

The positive rate of influenza viruses nationwide continues to rise, and the sales of Against Influenza drugs continue to grow.

① According to the latest data from the China Center for Disease Control and Prevention, the positivity rate of influenza viruses continues to rise, with over 99% being type A influenza. ② As the number of influenza infections increases, the sales of antiviral drugs against influenza have also been growing recently. Currently, the antiviral flu medications available domestically mainly include Oseltamivir, Abidol, Mabalaosavir, Zanamivir, and Peramivir.

cls.cnJan 6 08:05